Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01422421
Other study ID # H21-rinsho shiken ippan-017
Secondary ID
Status Recruiting
Phase Phase 4
First received August 23, 2011
Last updated March 25, 2018
Start date August 2011
Est. completion date December 2029

Study information

Verified date March 2018
Source Kyoto University, Graduate School of Medicine
Contact Shinichiro Ueda, MD, PhD
Phone +81-98-895-1195
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether intensive blood pressure and low density lipoprotein (LDL) cholesterol lowering could improve survival and cardiovascular outcome in Japanese diabetic patients with coronary artery disease and history of acute coronary syndrome.


Prevalence of type 2 diabetes in Asia seems to be almost epidemic and establishment of preventive strategy against macrovascular as well as microvascular diseases are warranted because of higher cardiovascular risk in diabetic patients even without history of atherosclerotic cardiovascular diseases. Benefit of lowering low density lipoprotein (LDL) cholesterol down to 70 mg/ml in Caucasian patients with coronary artery disease (CAD) has been well established but not in Asian patients with lower risk of myocardial infarction and higher stroke risk. Intensive lowering blood pressure for cardiovascular outcome in diabetic patients and patients with CAD has been recommended in several guidelines without firm evidence. Risk and benefit of intensive blood pressure and LDL control should be evaluated in Japanese diabetic CAD patients by pragmatic randomized controlled trial.

Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date December 2029
Est. primary completion date March 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Type 2 diabetic patients with coronary artery disease and history of acute coronary syndrome

- Patients whose blood pressure and LDL cholesterol levels are above values recommended by the current guideline

Exclusion Criteria:

- Patients who have active malignant tumor

- Patients who are on hemodialysis due to end stage kidney disease

- Patients whom statins are contraindicated

- Patients who had acute coronary syndrome or stroke within 3 months

- Patients who are pregnant or on breast feeding

- Patients whose physicians deem that attending this trial is contraindicated or inappropriate

Study Design


intensive control
use any medication to achieve systolic blood pressure less than 120mmHg and LDL cholesterol within 70-85mg/dl
standard control
use any medication to achieve systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl


Country Name City State
Japan University Hospital, University of the Ryukyus Nishihara Okinawa
Japan Saga University Hospital Saga

Sponsors (2)

Lead Sponsor Collaborator
Takeshi Morimoto University of the Ryukyus

Country where clinical trial is conducted



Type Measure Description Time frame Safety issue
Primary composite endpoint composite endpoint consisting of all-cause mortality, non-fatal myocardial infarction, non-fatal stroke and unstable angina requiring hospital administration 3 years
Primary important secondary composite endpoint composite endpoint consisting of all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, unstable angina requiring hospital administration, and admission for heart failure 3 years
Secondary all-cause mortality death due to any cause 3 years
Secondary myocardial infarction non fatal myocardial infarction 3 years
Secondary stroke non fatal stroke excluding transient ischemic attack 3 years
Secondary Cardiovascular death Cardiovascular death 3 years
Secondary end stage renal disease end stage renal disease needs kidney transplantation or hemodialysis 3 years
Secondary peripheral artery disease peripheral artery disease 3 years
Secondary new onset or deterioration of heart failure new onset or deterioration of heart failure 3 years
See also
  Status Clinical Trial Phase
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Recruiting NCT03632668 - Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072 Phase 1
Recruiting NCT02699645 - Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Phase 3
Completed NCT03170752 - Implementing and Testing a Cardiovascular Assessment Screening Program (CASP) N/A
Recruiting NCT03660631 - Dissemination of the Cardiovascular Risk Service N/A
Recruiting NCT03266510 - Inspiratory Muscle Strength Training to Improve Blood Pressure and Physiological Function N/A
Recruiting NCT02796313 - Diet Intervention for Hypertension: Adaptation and Dissemination to Native Communities N/A
Completed NCT00508365 - Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives Phase 1
Completed NCT00382564 - Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease N/A
Recruiting NCT03503773 - The TARGET BP OFF-MED Trial Phase 2
Not yet recruiting NCT03678207 - The Effectiveness of a Preoperative Blood Pressure Screening Program to Identify Undiagnosed Hypertension in Ambulatory Surgery Patients
Recruiting NCT03249753 - The Effect of Food Intake on the Pharmacokinetic of Single Dose SPH3127 Tablets in Chinese Health Subjects Phase 1
Completed NCT03100812 - Asian American Partnerships in Research and Empowerment (AsPIRE) N/A
Recruiting NCT03099343 - Tailored Messaging to Reduce Sodium Intake N/A
Active, not recruiting NCT03288142 - The Smart Hypertension Control Study N/A
Completed NCT02147626 - Heart Health 4 Moms N/A
Not yet recruiting NCT03661177 - Reclaiming Indigenous Food and Health N/A
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Safety and Efficacy of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Withdrawn NCT03292393 - Social Norms and Antihypertensive Medication Adherence N/A
Not yet recruiting NCT01620788 - Comparison of Losartan Associated With Indapamide Versus Hyzaar® in the Hypertension Treatment Phase 3